Physical stressors can impact metabolic health—here's where research lands regarding the effects of chronic stress on ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Neuropathy affects millions of people worldwide, causing chronic pain, numbness, weakness, and loss of function in the ...

Researchers at King’s College London have developed a powerful new AI model that can predict a person’s risk of ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Healthcare providers label patients with diagnoses that often cause anxiety and distress. A better approach is to rename a diagnosis as an imbalance to empower the patient.

GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

Diabetes Alert Day recognizes diabetes and its complications. One condition, known as diabetic peripheral neuropathy, affects ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re still available on some websites.

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

The No. 1 reason physicians cite for not prescribing a continuous glucose monitor is its complexity, a roadblock that DME ...